The recall affects around 14.76 lakh bottles of Atomoxetine Capsules in various strengths, produced by Glenmark ...

According to the U.S. health agency, Glenmark Pharmaceuticals is recalling over 15 lakh bottles of a generic drug used to ...

Glenmark Pharmaceuticals recalls 14.76 lakh bottles of Atomoxetine Capsules in the US due to impurity concerns.

Glenmark Pharmaceuticals is recalling 15 lakh bottles of Atomoxetine Capsules in the US due to an N-Nitroso Atomoxetine ...

Glenmark Pharmaceuticals Inc, USA, an arm of the Mumbai-based Glenmark Pharmaceuticals, is recalling around 14.76 lakh ...

ADHD is a neurodevelopmental disorder that affects a person's ability to focus, control impulses, and regulate their activity ...

Glenmark Pharmaceuticals, a global pharmaceutical giant, is recalling nearly 15 lakh bottles of Atomoxetine capsules from the ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions, dosage and administration, and place in therapy of atomoxetine in the treatment of attention-deficit ...

Glenmark Pharmaceuticals Inc, USA, a subsidiary of the Mumbai-based drug maker, is recalling around 14.76 lakh bottles of ...

Clinical trial data indicate that atomoxetine is safe and well tolerated for the treatment of ADHD; however, safety data about long-term use (greater than one year) are unavailable. Adverse events ...